• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

VIS Quiz Question #2

Poll

2. The NCVIA mandates that VIS sheets be given to persons receiving covered vaccines in which of the following groups?

A. All children under the age of 18 years
B. All persons receiving state or federal supplied vaccines, including vaccines not covered by the NCVIA
C. A and B
D. All persons receiving a covered vaccine
Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Excess Intake of Ultraprocessed Foods Tied to Higher Cardiometabolic Risk, AHA Advisory Says

Excess Intake of Ultraprocessed Foods Tied to Higher Cardiometabolic Risk, AHA Advisory Says

Sydney Jennings
August 8th 2025
Article

The advisory panel laid out 4 priority actions for clinicians, policymakers, and industry.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
August 7th 2025
Podcast

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose

Sydney Jennings
August 8th 2025
Article

Your daily dose of the clinical news you may have missed.

Make It Routine: Screening for Cognitive Decline in Primary Care

Make It Routine: Screening for Cognitive Decline in Primary Care

Anna Chodos, MD, MPH;Sydney Jennings
July 24th 2025
Podcast

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

Lilly's Oral GLP-1 Agonist Orforglipron Linked to Weight Reduction of 12.4% in Pivotal Phase 3 Trial / image credit ©MichaelVI/stock.adobe.com

Lilly's Oral GLP-1 Agonist Orforglipron Linked to Weight Reduction of 12.4% in Pivotal Phase 3 Trial

Grace Halsey
August 7th 2025
Article

The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.

Study Sheds Light on Public Perception of Physicians Who Use AI: Daily Dose / image credit: ©New Africa/AdobeStock

Study Sheds Light on Public Perception of Physicians Who Use AI: Daily Dose

Sydney Jennings
August 7th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.